MANATT, PHELPS, AND PHILLIPS

Lobbying for DENALI THERAPEUTICS · Biopharmaceutical Company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · $70,000.00 income · posted Oct 15, 2025

Lobbying activity 1

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.